Rastogi Vaibhav, Singh Devina, Kaur Babbaljeet, Arora Pulkit, Gadikota Jaya P
Department of Medicine, University of Central Florida.
College of Medicine, University of Central Florida.
Cureus. 2018 May 29;10(5):e2705. doi: 10.7759/cureus.2705.
Levetiracetam is an anti-epileptic that works at the synapse and binds synapse vesicle protein 2A, thereby controlling the release of neurotransmitters. Its side effects mainly include somnolence, headache, fatigue, dizziness, vomiting, and behavioral alterations. Rhabdomyolysis is a rare adverse effect of levetiracetam. The underlying pathophysiology of this adverse effect is unknown. Our patient is a 42-year-old male who was brought to the hospital with a complaint of generalized tonic-clonic seizures and urinary incontinence. His symptoms were caused by hyponatremia. Levetiracetam was started for seizure prevention along with management for hyponatremia. His creatine phosphokinase levels increased on the third day of admission to 30,000 U/L. Four days after the discontinuation of levetiracetam and with the institution of supportive therapy, the patient's rhabdomyolysis resolved.
左乙拉西坦是一种作用于突触并与突触囊泡蛋白2A结合的抗癫痫药物，从而控制神经递质的释放。其副作用主要包括嗜睡、头痛、疲劳、头晕、呕吐和行为改变。横纹肌溶解是左乙拉西坦罕见的不良反应。这种不良反应的潜在病理生理学尚不清楚。我们的患者是一名42岁男性，因全身性强直阵挛发作和尿失禁入院。他的症状是由低钠血症引起的。开始使用左乙拉西坦预防癫痫发作并同时治疗低钠血症。入院第三天他的肌酸磷酸激酶水平升至30,000 U/L。停用左乙拉西坦并给予支持性治疗四天后，患者的横纹肌溶解症状得到缓解。
